サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：前立腺がんの世界市場の評価：タイプ別、がんステージ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）
市場調査レポート
商品コード
1394593

前立腺がんの世界市場の評価：タイプ別、がんステージ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）

Prostate Cancer Market Assessment, By Types, By Stages of Cancer, By Modality, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 204 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
前立腺がんの世界市場の評価：タイプ別、がんステージ別、モダリティ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）
出版日: 2023年12月13日
発行: Market Xcel - Markets and Data
ページ情報: 英文 204 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺がんの市場規模は、2022年の117億1,000万米ドルから2030年に218億4,000万米ドルに達し、2023年～2030年の予測期間にCAGRで8.1％の成長が見込まれています。さまざまな要素が市場に作用し、その有病率、診断、治療、研究に影響を及ぼしています。市場の主な促進要因は、高齢化、世界の前立腺がんの負担の増大、診断ツールの進歩、早期発見とスクリーニング、遺伝子研究、意識向上と教育、治療法の革新、医療へのアクセス、疫学動向、規制環境、医療費の上昇、遠隔医療とデジタルヘルス技術の採用などです。

市場に影響を与えているもっとも顕著な要因の1つは高齢化です。前立腺がんは年齢と密接な相関関係があるため、世界の人々が高齢化するにつれて、前立腺がんの罹患率が大幅に上昇します。診断ツールの進歩も、市場を牽引する極めて重要な役割を果たしています。MRIやPETスキャンのような画像診断技術の革新は、前立腺がんの診断精度を高め、より早期かつ正確な同定につながっています。早期発見とスクリーニングプログラム、特に広く用いられているPSA（前立腺特異抗原）検査は、前立腺がんの早期発見に役立っています。遺伝学的研究は前立腺がんの理解を一変させ、その根底にある分子的、遺伝的メカニズムを解明しました。この知識は、個々の患者の特異的な遺伝子構成に合わせて治療戦略を調整する標的療法や精密医療アプローチへの道を開きました。

意識向上キャンペーンや教育キャンペーンは、定期的な検診とスクリーニングの重要性に対する人々の意識を高めました。製薬産業における治療法の革新は、標的療法や免疫療法を含む新しい医薬品や治療法を導入しました。こうした技術革新は、より効果的な治療オプションを提供し、研究開発への投資を刺激して、世界の前立腺がん市場を前進させています。医療へのアクセス、疫学動向、規制環境、医療費の増加は、いずれも相互に影響し合い、世界の前立腺がん市場情勢を形成しています。医療サービスへのアクセスにおける格差や、地域および世界の経済的/社会的要因は、前立腺がんの診断と治療に影響を与えます。さらに、遠隔医療やデジタルヘルス技術の採用は医療サービスの範囲を拡大し、前立腺がん患者の遠隔での診察やモニタリングを容易にしています。この進化は、医療サービスが行き届いていない地域や、直接の受診が制限されるような健康危機において特に重要です。

政府の取り組み

世界各国の政府は、啓発プログラムや財政支援などの多面的なアプローチを通じて、前立腺がんの罹患率の上昇に積極的に対処しています。こうした取り組みは、世界の前立腺がん市場を強化する上で極めて重要な役割を果たしています。啓発キャンペーンは、リスクと早期発見の重要性について公衆を教育するだけでなく、この疾患にまつわる偏見を減らし、より多くの男性が検診を受けるよう促します。政府の財政援助は、研究、医療インフラ、患者の治療へのアクセスを支援しています。このような複合的なアプローチが、世界の前立腺がん市場の全体的な拡大に寄与しています。一例として、カナダ政府は2023年9月、前立腺がんを含むさまざまな健康問題を対象とした啓発キャンペーンを発表しました。政府はCanadian Partnership Against Cancer（CPAC）に年間5,000万米ドルの予算を割り当てることで、高いがん罹患率に積極的に対処しています。この資金援助を受け、CPACはCanadian Cancer Societyと共同で、2023年7月にカナダ初のがんに特化したデータイニシアチブを導入し、これはThe Pan-Canadian Cancer Data Strategyとして知られています。この戦略は、がん関連データの収集、統合、活用を改善する取り組みの指針となるよう設計されており、最終的には、がんの転帰を改善し、カナダ全土におけるがん医療の質と公平性を高めることを目的としています。

当レポートでは、世界の前立腺がん市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界の前立腺がん市場の将来の見通し

第4章 エグゼクティブサマリー

第5章 世界の前立腺がん市場の見通し（2016年～2030年）

  • 市場規模と予測
    • 金額
    • 数量
  • タイプ別
    • 腺がん
    • 移行上皮がん
    • 扁平上皮がん
    • 前立腺小細胞がん
    • その他
  • がんステージ別
    • 限局性前立腺がん
    • 局所進行性前立腺がん
    • 進行性/転移性前立腺がん
  • モダリティ別
    • 診断
    • 治療
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • 専門クリニック
    • 薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • 南米
    • アジア太平洋
    • 中東・アフリカ
  • 市場シェア：企業別（2022年）

第6章 世界の前立腺がん市場の見通し：地域別（2016年～2030年）

  • 北米
    • タイプ別
    • がんステージ別
    • モダリティ別
    • エンドユーザー別
    • 米国
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第7章 市場マッピング（2022年）

  • タイプ別
  • がんステージ別
  • モダリティ別
  • エンドユーザー別
  • 地域別

第8章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第9章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第10章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第11章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2022年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社）
  • 特許分析（該当する場合）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

  • AstraZeneca plc
  • Merck & Co., Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Sanofi S.A.
  • Johnson & Johnson Innovative Medicine
  • Dendreon Pharmaceuticals LLC.
  • Pfizer, Inc.
  • Clovis Oncology, Inc.
  • AbbVie, Inc.

第15章 戦略的推奨事項

第16章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 3. Global Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 4. Global Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 5. Global Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 6. Global Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 7. Global Prostate Cancer Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 10. North America Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 11. North America Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 12. North America Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 13. North America Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 14. North America Prostate Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 17. United States Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 18. United States Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 19. United States Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 20. United States Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 21. Canada Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 23. Canada Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 24. Canada Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 25. Canada Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 26. Canada Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 27. Mexico Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 29. Mexico Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 30. Mexico Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 31. Mexico Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 32. Mexico Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 33. Europe Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 35. Europe Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 36. Europe Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 37. Europe Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 38. Europe Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 39. Europe Prostate Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 42. Germany Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 43. Germany Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 44. Germany Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 45. Germany Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 46. France Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 48. France Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 49. France Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 50. France Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 51. France Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 52. Italy Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 54. Italy Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 55. Italy Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 56. Italy Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 57. Italy Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 60. United Kingdom Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 64. Russia Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 66. Russia Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 67. Russia Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 68. Russia Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 69. Russia Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 70. Netherlands Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 72. Netherlands Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 73. Netherlands Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 74. Netherlands Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 75. Netherlands Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 76. Spain Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 78. Spain Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 79. Spain Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 80. Spain Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 81. Spain Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 82. Turkey Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 84. Turkey Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 85. Turkey Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 86. Turkey Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 87. Turkey Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 88. Poland Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 90. Poland Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 91. Poland Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 92. Poland Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 93. Poland Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 94. South America Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 96. South America Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 97. South America Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 98. South America Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 99. South America Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 100. South America Prostate Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 103. Brazil Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 104. Brazil Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 105. Brazil Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 106. Brazil Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 107. Argentina Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 109. Argentina Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 110. Argentina Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 111. Argentina Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 112. Argentina Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 115. Asia-Pacific Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific Prostate Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 122. India Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 123. India Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 124. India Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 125. India Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 126. China Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 128. China Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 129. China Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 130. China Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 131. China Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 132. Japan Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 134. Japan Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 135. Japan Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 136. Japan Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 137. Japan Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 138. Australia Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 140. Australia Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 141. Australia Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 142. Australia Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 143. Australia Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 144. Vietnam Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 146. Vietnam Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 147. Vietnam Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 148. Vietnam Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 149. Vietnam Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 150. South Korea Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 152. South Korea Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 153. South Korea Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 154. South Korea Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 155. South Korea Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 156. Indonesia Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 158. Indonesia Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 159. Indonesia Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 160. Indonesia Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 161. Indonesia Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 162. Philippines Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 164. Philippines Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 165. Philippines Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 166. Philippines Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 167. Philippines Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 170. Middle East & Africa Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa Prostate Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 177. Saudi Arabia Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 181. UAE Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 183. UAE Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 184. UAE Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 185. UAE Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 186. UAE Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 187. South Africa Prostate Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa Prostate Cancer Market, By Volume, In Million, 2016-2030F
  • Figure 189. South Africa Prostate Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 190. South Africa Prostate Cancer Market Share, By Stages of Cancer, In USD Billion, 2016-2030F
  • Figure 191. South Africa Prostate Cancer Market Share, By Modality, In USD Billion, 2016-2030F
  • Figure 192. South Africa Prostate Cancer Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Stages of Cancer Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
目次
Product Code: MX10744

Global Prostate Cancer Market size was valued at USD 11.71 billion in 2022, which is expected to reach USD 21.84 billion in 2030 with a CAGR of 8.1% for the forecast period between 2023 and 2030F. Various elements affect the global prostate cancer market, influencing its prevalence, diagnosis, treatment, and research. Among the significant factors driving the global prostate cancer market are the aging population, increasing global burden of prostate cancer, advancements in diagnostic tools, early detection and screening, genetic research, awareness and education, therapeutic innovation, access to healthcare, epidemiological trends, the regulatory environment, rising healthcare expenditure, and the adoption of telemedicine and digital health technologies.

One of the most prominent factors impacting the global prostate cancer market is the aging population. As the world's population continues to grow older, the incidence of prostate cancer rises significantly since this disease is closely correlated with age. Advancements in diagnostic tools have also played a pivotal role in driving the global prostate cancer market. Innovations in imaging techniques like MRI and PET scans have enhanced the precision of prostate cancer diagnosis, leading to earlier and more accurate identification of the disease. Early detection and screening programs, particularly the widely used PSA (prostate-specific antigen) test, have been instrumental in identifying prostate cancer in its early stages. Genetic research has revolutionized the understanding of prostate cancer, elucidating its underlying molecular and genetic mechanisms. This knowledge has paved the way for targeted therapies and precision medicine approaches, tailoring treatment strategies to the specific genetic makeup of individual patients.

Awareness and education campaigns have heightened public consciousness about the importance of regular check-ups and screenings. Therapeutic innovation within the pharmaceutical industry has introduced novel drugs and treatment modalities, including targeted therapies and immunotherapies. These innovations provide more effective treatment options and stimulate investment in research and development, propelling the global prostate cancer market forward. Access to healthcare, epidemiological trends, regulatory environments, and rising healthcare expenditure all interact to shape the landscape of the global prostate cancer market. Disparities in access to healthcare services, coupled with regional and global economic and social factors, impact the diagnosis and treatment of prostate cancer. Furthermore, adopting telemedicine and digital health technologies has expanded the reach of healthcare services, facilitating remote consultations and monitoring for prostate cancer patients. This evolution is particularly vital in underserved areas or during times of health crises when in-person visits may be limited.

Global Burden of Prostate Cancer

Prostate cancer is a widespread concern, affecting millions of men worldwide. It stands as the second most prevalent cancer in men, trailing only behind lung cancer, and contributes to 14.1% of all newly diagnosed cancer cases among men on a global scale, boosting the global prostate cancer market. Remarkably, in 112 countries, it ranks as the most frequently identified cancer in the male population. The year 2020 saw an estimated 1.41 million new cases of prostate cancer reported, with a sobering 375,304 deaths attributed to the disease across the globe. These distressing statistics place prostate cancer among the foremost causes of cancer-related mortality in men. Age plays a substantial role in the risk associated with prostate cancer, with over 85% of newly diagnosed patients being older than 60 years. Furthermore, a wide array of factors, including modifiable behaviors, prostate-specific antigen (PSA) screeni ng, metabolic attributes, and environmental influences, have been suggested as contributors to the varying epidemiological impact of the disease. Notably, the incidence and mortality rates of prostate cancer exhibit disparities according to ethnicity and geographical location. Developed countries such as North America, Western and Northern Europe, and Australia show higher prevalence rates compared to their developing counterparts, likely due to factors like a higher human development index (HDI), greater gross domestic product, and, subsequently, extended life expectancy.

Increased Awareness

Heightened awareness programs significantly influence the growth of the global prostate cancer market. These initiatives have played a vital role in educating individuals about the risks, symptoms, and the importance of regular screenings for prostate cancer. As a result, more men proactively seek early detection and treatment, thus increasing the demand for diagnostic and therapeutic services. Greater awareness fosters early intervention, improving outcomes and a higher survival rate. Consequently, the global prostate cancer market expands as a direct consequence of these educational efforts. For example, in December 2022, AstraZeneca unveiled "Never Miss," a global prostate cancer awareness campaign developed in collaboration with Merck & Co., rolled out in the United States and Canada. This initiative leverages the widespread enthusiasm for sports to motivate individuals to comprehend their susceptibility to prostate cancer. It also encourages those at risk to converse with their healthcare professionals.

Government Initiatives

Governments worldwide are actively addressing the rising incidence of prostate cancer through multifaceted approaches, including awareness programs and financial support. These efforts play a pivotal role in bolstering the global prostate cancer market. Awareness campaigns not only educate the public about the risks and importance of early detection but also reduce the stigma surrounding the disease, encouraging more men to seek screenings. Government financial aids support research, healthcare infrastructure, and patient access to treatments. This combined approach contributes to the overall expansion of the global prostate cancer market. As an example, in September 2023, the Canadian government unveiled awareness campaigns targeting various health issues, including prostate cancer. The government is actively addressing high cancer incidence rates by allocating an annual budget of $50 million to the Canadian Partnership Against Cancer (CPAC). With this financia l support, CPAC, in collaboration with the Canadian Cancer Society, introduced Canada's inaugural cancer-specific data initiative, known as The Pan-Canadian Cancer Data Strategy, in July 2023. This strategy is designed to guide efforts in improving the collection, integration, and utilization of cancer-related data, ultimately aiming to enhance cancer outcomes and elevate the quality and equity of cancer care throughout Canada.

Chemotherapy-popular choice

Chemotherapy is a widely sought-after treatment for prostate cancer, and its prominence contributes significantly to the expansion of the global prostate cancer market. Chemotherapy involves the use of powerful drugs to target and kill cancer cells, making it a crucial option, especially for advanced or aggressive prostate cancer cases. As the incidence of prostate cancer continues to rise globally, the demand for effective treatment options, including chemotherapy, remains high. This growing demand propels the development of new chemotherapy drugs and therapies, fostering innovation and investment in the market. Moreover, it plays a pivotal role in improving the overall outlook for prostate cancer patients. As an example, in August 2023, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, disclosed that the U.S. Food & Drug Administration (FDA) granted approval for AKEEGA (niraparib and abiraterone acetate). This marks the first-ever dual-action tablet to combine a PARP inhibitor with abiraterone acetate, administered alongside prednisone. The approval is specifically for the treatment of adult patients who have either confirmed deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) or suspected deleterious BRCA mutations as identified by an FDA-sanctioned test.

Growing Demand for Screening Tests

The global prostate cancer market is witnessing a growing demand for screening tests due to several key factors. Firstly, heightened awareness campaigns and educational efforts have encouraged men to be proactive about their health, increasing their willingness to undergo screening. Secondly, the aging population, which is more susceptible to prostate cancer, contributes to a higher demand for these tests. Additionally, advancements in diagnostic technologies have made screenings more accurate and accessible. This surge in demand for screening tests facilitates early detection and drives the growth of the prostate cancer market by necessitating further diagnostic and treatment services. As an example, LynxDx, a diagnostic solutions developer, introduced a novel non-invasive urine test for prostate cancer screening called MyProstateScore 2.0 (MPS2) in February 2023. This data-driven test is specifically tailored to deliver precise and categorized risk assessment information, aiding healthcare professionals in making clinical decisions for individuals with elevated prostate-specific antigen (PSA) levels or abnormal findings in digital rectal exams (DRE).

Future Outlook of Global Prostate Cancer Market

The future of the global prostate cancer market holds tremendous promise. Several factors contribute to this optimistic outlook. First and foremost, the aging population is on the rise, and prostate cancer is closely linked to age, ensuring a consistent demand for diagnosis and treatment. Advances in diagnostic tools, such as imaging technologies and genetic research, have improved early detection and personalized treatment strategies. The pharmaceutical industry continues to innovate with the introduction of targeted therapies and immunotherapies, offering more effective and precise treatment options. Awareness campaigns and proactive screening efforts have increased public consciousness about the importance of regular check-ups, leading to early diagnosis and intervention. Additionally, the adoption of telemedicine and digital health technologies has expanded healthcare access, particularly in underserved areas or during crises. These factors collectively create a bright future for the global prostate cancer market, ensuring better patient outcomes and continued growth.

Key Players Landscape and Outlook

In the global prostate cancer market, prominent companies are increasingly forging collaborative partnerships to advance the development of innovative and more efficacious pharmaceutical treatments. This strategic trend reflects the industry's recognition of the complex challenges posed by prostate cancer, encouraging joint research efforts and shared expertise. These collaborations aim to expedite the discovery and approval of novel drugs, which can offer improved therapeutic outcomes for patients, reduce side effects, and improve overall treatment effectiveness. By pooling resources and knowledge, these partnerships hold the potential to drive significant advancements in prostate cancer therapy, benefiting both patients and the healthcare industry. For example, in June 2023, the US Food and Drug Administration (FDA) authorized the use of a combination treatm ent involving AstraZeneca and MSD's Lynparza (Olaparib) along with conventional therapies for the management of metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations (BRCAm). This approval pertains to the utilization of Lynparza alongside the standard medications Zytiga and prednisone for mCRPC.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Future Outlook of Global Prostate Cancer Market

4. Executive Summary

5. Global Prostate Cancer Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. Value
    • 5.1.2. Volume
  • 5.2. By Types
    • 5.2.1. Adenocarcinoma
    • 5.2.2. Transitional Cell Carcinoma
    • 5.2.3. Squamous Cell Carcinoma
    • 5.2.4. Small Cell Prostate Cancer
    • 5.2.5. Others
  • 5.3. By Stages of Cancer
    • 5.3.1. Localised Prostate Cancer
    • 5.3.2. Localised-advanced Prostate Cancer
    • 5.3.3. Advanced/Metastatic Prostate Cancer
  • 5.4. By Modality
    • 5.4.1. Diagnosis
      • 5.4.1.1. Digital Rectal Examination
      • 5.4.1.2. Prostate-specific Antigen Blood Test
      • 5.4.1.3. Transrectal Ultrasound
      • 5.4.1.4. Magnetic Resonance Imaging
      • 5.4.1.5. PSMA PET scan
    • 5.4.2. Treatment
      • 5.4.2.1. Surgery
      • 5.4.2.2. Radiation Therapy
      • 5.4.2.3. Radiopharmaceuticals
      • 5.4.2.4. Hormone Therapy
      • 5.4.2.5. Chemotherapy
      • 5.4.2.6. Immunotherapy
      • 5.4.2.7. Bisphosphonate Therapy
      • 5.4.2.8. Cryotherapy
      • 5.4.2.9. High-Intensity Focused Ultrasound
      • 5.4.2.10. Prostate Cancer Vaccine
  • 5.5. By End-user
    • 5.5.1. Hospitals
    • 5.5.2. Ambulatory Surgical Centers
    • 5.5.3. Specialty Clinics
    • 5.5.4. Pharmacies
    • 5.5.5. Others
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. South America
    • 5.6.4. Asia-Pacific
    • 5.6.5. Middle East and Africa
  • 5.7. By Company Market Share (%), 2022

6. Global Prostate Cancer Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. By Types
      • 6.1.1.1. Adenocarcinoma
      • 6.1.1.2. Transitional Cell Carcinoma
      • 6.1.1.3. Squamous Cell Carcinoma
      • 6.1.1.4. Small Cell Prostate Cancer
      • 6.1.1.5. Others
    • 6.1.2. By Stages of Cancer
      • 6.1.2.1. Localised Prostate Cancer
      • 6.1.2.2. Localised-advanced Prostate Cancer
      • 6.1.2.3. Advanced/Metastatic Prostate Cancer
    • 6.1.3. By Modality
      • 6.1.3.1. Diagnosis
      • 6.1.3.1.1. Digital Rectal Examination
      • 6.1.3.1.2. Prostate-specific Antigen Blood Test
      • 6.1.3.1.3. Transrectal Ultrasound
      • 6.1.3.1.4. Magnetic Resonance Imaging
      • 6.1.3.1.5. PSMA PET scan
      • 6.1.3.2. Treatment
      • 6.1.3.2.1. Surgery
      • 6.1.3.2.2. Radiation Therapy
      • 6.1.3.2.3. Radiopharmaceuticals
      • 6.1.3.2.4. Hormone Therapy
      • 6.1.3.2.5. Chemotherapy
      • 6.1.3.2.6. Immunotherapy
      • 6.1.3.2.7. Bisphosphonate Therapy
      • 6.1.3.2.8. Cryotherapy
      • 6.1.3.2.9. High-Intensity Focused Ultrasound
      • 6.1.3.2.10. Prostate Cancer Vaccine
    • 6.1.4. By End-user
      • 6.1.4.1. Hospitals
      • 6.1.4.2. Ambulatory Surgical Centers
      • 6.1.4.3. Specialty Clinics
      • 6.1.4.4. Pharmacies
      • 6.1.4.5. Others
    • 6.1.5. United States*
      • 6.1.5.1. By Types
      • 6.1.5.1.1. Adenocarcinoma
      • 6.1.5.1.2. Transitional Cell Carcinoma
      • 6.1.5.1.3. Squamous Cell Carcinoma
      • 6.1.5.1.4. Small Cell Prostate Cancer
      • 6.1.5.1.5. Others
      • 6.1.5.2. By Stages of Cancer
      • 6.1.5.2.1. Localised Prostate Cancer
      • 6.1.5.2.2. Localised-advanced Prostate Cancer
      • 6.1.5.2.3. Advanced/Metastatic Prostate Cancer
      • 6.1.5.3. By Modality
      • 6.1.5.3.1. Diagnosis
      • 6.1.5.3.1.1. Digital Rectal Examination
      • 6.1.5.3.1.2. Prostate-specific Antigen Blood Test
      • 6.1.5.3.1.3. Transrectal Ultrasound
      • 6.1.5.3.1.4. Magnetic Resonance Imaging
      • 6.1.5.3.1.5. PSMA PET scan
      • 6.1.5.3.2. Treatment
      • 6.1.5.3.2.1. Surgery
      • 6.1.5.3.2.2. Radiation Therapy
      • 6.1.5.3.2.3. Radiopharmaceuticals
      • 6.1.5.3.2.4. Hormone Therapy
      • 6.1.5.3.2.5. Chemotherapy
      • 6.1.5.3.2.6. Immunotherapy
      • 6.1.5.3.2.7. Bisphosphonate Therapy
      • 6.1.5.3.2.8. Cryotherapy
      • 6.1.5.3.2.9. High-Intensity Focused Ultrasound
      • 6.1.5.3.2.10. Prostate Cancer Vaccine
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Hospitals
      • 6.1.5.4.2. Ambulatory Surgical Centers
      • 6.1.5.4.3. Specialty Clinics
      • 6.1.5.4.4. Pharmacies
      • 6.1.5.4.5. Others
      • 6.1.5.5. Canada
      • 6.1.5.6. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1 Germany
    • 6.2.2 France
    • 6.2.3 Italy
    • 6.2.4 United Kingdom
    • 6.2.5 Russia
    • 6.2.6 Netherlands
    • 6.2.7 Spain
    • 6.2.8 Turkey
    • 6.2.9 Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Types
  • 7.2. By Stages of Cancer
  • 7.3. By Modality
  • 7.4. By End-user
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis
  • 8.3. Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. AstraZeneca plc
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Merck & Co., Inc.
  • 14.3. Astellas Pharma Inc.
  • 14.4. Bayer AG
  • 14.5. Sanofi S.A.
  • 14.6. Johnson & Johnson Innovative Medicine
  • 14.7. Dendreon Pharmaceuticals LLC.
  • 14.8. Pfizer, Inc.
  • 14.9. Clovis Oncology, Inc.
  • 14.10. AbbVie, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer